No, cancer has not been cured. Moderna and Merck announced on August 19, 2026, that their personalized mRNA treatment helped people with high-risk melanoma live longer without the disease returning or spreading than Merck’s Keytruda alone. It is a potentially historic advance for one cancer, in one carefully defined setting—not proof that all cancers can now be eliminated.

The experimental treatment, called intismeran autogene, was tested after patients had surgery that completely removed stage IIB through IV melanoma. In the 1,137-person Phase 3 INTerpath-001 trial, two patients received intismeran plus Keytruda for every one who received Keytruda alone.

The companies said the combination produced statistically significant and clinically meaningful improvements in recurrence-free survival and distant-metastasis-free survival. That means it delayed either the cancer’s return, its spread to another part of the body, or death as defined by the trial. It does not mean every patient remained cancer-free.

The short answer

The result matters because this is the first positive Phase 3 readout for an individualized neoantigen treatment and for an mRNA-based cancer therapy, according to Moderna and Merck. Phase 3 is the pivotal stage generally used to support regulatory decisions.

But the announcement was a top-line company release, not a full presentation of the data. Moderna and Merck did not disclose how large the benefit was, how many patients relapsed in each group, or whether the treatment helped people live longer overall. The trial is continuing to evaluate overall survival, and the companies plan to present detailed findings at an international medical meeting and discuss possible filings with regulators.

Why this is called a vaccine

Intismeran is not a preventive shot like a measles or COVID-19 vaccine. It is made after a person’s tumor is removed and analyzed. Scientists identify mutations unique to that tumor and create a custom mRNA sequence encoding as many as 34 neoantigens—abnormal markers that can help the immune system recognize cancer cells.

Patients in the combination group received up to nine intismeran doses over roughly six months and Keytruda for about a year. Keytruda blocks the PD-1 pathway, which cancers can exploit to hide from immune attack. The personalized mRNA treatment is designed to give the immune system a more specific target while Keytruda helps keep that response active.

What the result does not show

The study did not test the therapy as a replacement for surgery. It did not test intismeran by itself. It did not show that the treatment works across every cancer type. It also has not established a cure, which would require longer follow-up and evidence that patients remain disease-free without excess deaths or unacceptable harm.

The companies said the safety profile was consistent with earlier studies and that no new safety signals appeared, but detailed Phase 3 adverse-event data have not yet been released. Earlier evidence was encouraging, but the new randomized trial’s full numbers will determine how compelling the benefit really is.

What happens next

Regulators will need the complete efficacy and safety package before deciding whether intismeran can be approved. Doctors will also want to know the absolute reduction in recurrence, which patient groups benefited most, how long protection lasts, how quickly each personalized dose can be manufactured, and what the treatment would cost.

Moderna shares more than doubled after the announcement, reflecting investor hopes that the company’s mRNA platform can extend well beyond respiratory vaccines. The scientific takeaway is narrower but more important: a personalized treatment appears to have improved outcomes in a large late-stage melanoma trial. That is a milestone—not a cure for cancer.

This article provides general information and is not medical advice. Patients should discuss treatment decisions with a qualified oncology team.